Xenetic Biosciences, Inc. Warrants, also called Xenetic Biosciences Warrant, is a biopharmaceutical company, which focuses on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. Read More The company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The XCART has the potential to fuel a robust pipeline of therapeutic assets targeting oncology indications. Additionally, Xenetic is leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. The PolyXen has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. Xenetic Biosciences was founded on and is headquartered in Framingham, MA.